Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10895MR)

This product GTTS-WQ10895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ373MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ12131MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ7697MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ11814MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ9917MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ9551MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW